Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (473)	6/1/2000 3:25:00 PM
From: scaram(o)uche	Respond to of 805

just parking..... Thursday June 1, 3:00 pm Eastern Time Company Press Release SOURCE: NeuroNova AB NeuroNova AB Advances Stem Cell Research with Landmark Discovery; Stem Cells in Adult Mouse Brain Have Potential to Generate Cells of Other Organs STOCKHOLM, Sweden, June 1 /PRNewswire/ -- NeuroNova AB today announced that its affiliated scientific team at the Karolinska Institute in Stockholm has shown that stem cells in the adult mouse brain have the potential to generate a variety of cells for other organs such as the heart, liver, muscle, intestine and other tissues. The discovery indicates that adult brain stem cells may be a valuable research tool and may potentially be used to generate cells for transplantation in the treatment of diseases. This finding is reported in the June 2 issue of Science. Previously, on January 8, 1999 NeuroNova announced it had identified the stem cells in both the adult human and rodent brain, capable of generating new nerve and supporting cells. This finding was reported in Cell (January 8, 1999). This latest discovery by NeuroNova adds to the relatively new concept that adult animals, and potentially also humans, contain cells with an unexpected self-renewing capacity. ``It is very interesting that the fate of these cells from adults seems to be negotiable provided the biochemical environment is right. The potential of the finding is significant for the understanding of what directs a cell towards a certain destiny and it also creates opportunities to use this cell type for transplantation purposes outside the central nervous system'', stated Dr. Anders Haegerstrand, the recently appointed President and CEO of NeuroNova AB. Jonas Frisen, M.D., lead scientist of the team behind these new findings commented, ``We have demonstrated that the potency of these cells was far greater than expected and what seemed to be a fairly restricted cell type can give rise to many different types of cells. These recent findings may turn some previous concepts upside down '' NeuroNova AB is a medical scientific company established in Sweden in 1998. The Company's objective is to develop stem cell-based therapies for neurological disorders in the central nervous system. NeuroNova has been funded by the Swedish venture capital fund HealthCap, Novare Kapital AB and National Pension Insurance Fund -- Sixth Fund Board. The two scientific founders are Drs. Anne Marie Janson and Jonas Frisen, both of whom are scientists at the Karolinska Institute in Stockholm, Sweden. Dr Anders Haegerstrand was appointed President and CEO April 1st this year. His previous appointment was with AstraZeneca PLC within global management of Discovery CNS and Pain Control. For further information please turn to: NeuroNova's Web site or to the link to the scientific journal Science and the publication of above findings. neuronova.com scienceonline.org SOURCE: NeuroNova AB